Vor Biopharma Inc (VOR)

$22.25 +0.84 (3.92%)
Market Cap 1.15B
Revenue (ttm) 0.00
Net Income (ttm) -695.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 834,859
Avg Vol 1,255,746
Day's Range N/A - N/A
Shares Out 54.19M
Stochastic %K 84%
Beta 1.69
Analysts Strong Sell
Price Target $36.14

Company Profile

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
500 Boylston Street, Suite 1350, Boston, United States
pc247cz
pc247cz Aug. 4 at 2:20 PM
$HUMA strongly believe in this swing idea. Also holding $VOR a monster in making 😅
0 · Reply
Lizardbronsen
Lizardbronsen Aug. 3 at 2:45 PM
$SPY $FCUV $AMZN $VOR $SCYX
0 · Reply
atmostrunmoney
atmostrunmoney Aug. 3 at 2:27 PM
$VOR VOR & $OMER bullish….
0 · Reply
GSP
GSP Aug. 3 at 12:42 PM
$SPY $FCUV $AMZN $VOR $SCYX
0 · Reply
GSP
GSP Aug. 2 at 3:13 PM
Your Day Trading Watch List Video for August 3rd in About 3 Minutes: $SPY $FCUV $AMZN $VOR $SCYX .
0 · Reply
MikiTrader
MikiTrader Aug. 1 at 4:39 AM
$VOR
0 · Reply
pc247cz
pc247cz Jul. 31 at 8:01 PM
$VOR nice recovery
0 · Reply
GSP
GSP Jul. 31 at 11:39 AM
$AVEX $GCTK $VOR $CYCU $JLHL
0 · Reply
GSP
GSP Jul. 30 at 10:17 PM
Your Day Trading Watch List for July 31st in About 2 Minutes (con't): $AVEX $GCTK $VOR $CYCU $JLHL .
0 · Reply
pc247cz
pc247cz Jul. 30 at 7:55 PM
$VOR Jist wow. Still not selling. More to come. 🙏
0 · Reply
Latest News on VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 3, 2026, 4:30 PM EDT - 23 hours ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints David Zaccardelli to Board of Directors

Jul 7, 2026, 4:01 PM EDT - 4 weeks ago

Vor Bio Appoints David Zaccardelli to Board of Directors

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2026, 5:30 PM EDT - 4 weeks ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio announces China NMPA approval for telitacicept

2026-06-08T13:05:34.000Z - 2 months ago

Vor Bio announces China NMPA approval for telitacicept

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

Jun 8, 2026, 8:31 AM EDT - 2 months ago

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Jun 8, 2026, 8:30 AM EDT - 2 months ago

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Vor Biopharma Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:55 AM EDT - 2 months ago

Vor Biopharma Transcript: Jefferies Global Healthcare Conference 2026

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

May 28, 2026, 8:30 AM EDT - 2 months ago

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

Vor Bio price target raised to $18 from $15 at Wedbush

2026-05-14T17:08:10.000Z - 2 months ago

Vor Bio price target raised to $18 from $15 at Wedbush

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

May 14, 2026, 8:30 AM EDT - 2 months ago

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 8:30 AM EDT - 2 months ago

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Vor Biopharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

Vor Biopharma Quarterly report: Q1 2026

Vor Biopharma Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

Vor Biopharma Earnings release: Q1 2026

Vor Bio files to sell 5.34M shares of common stock for holders

2026-04-27T20:37:27.000Z - 3 months ago

Vor Bio files to sell 5.34M shares of common stock for holders

Vor Biopharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Vor Biopharma Proxy statement: Proxy filing

Vor Biopharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Vor Biopharma Proxy statement: Proxy filing

Vor Biopharma Registration statement: Registration filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Vor Biopharma Registration statement: Registration filing

Vor Bio price target lowered to $31 from $32 at H.C. Wainwright

2026-04-15T10:05:49.000Z - 3 months ago

Vor Bio price target lowered to $31 from $32 at H.C. Wainwright

Vor Bio price target raised to $15 from $9 at Wedbush

2026-03-31T11:58:58.000Z - 4 months ago

Vor Bio price target raised to $15 from $9 at Wedbush

Vor Bio price target lowered to $40 from $55 at Stifel

2026-03-30T18:36:48.000Z - 4 months ago

Vor Bio price target lowered to $40 from $55 at Stifel

Vor Bio price target lowered to $40 from $55 at Stifel

2026-03-30T18:30:12.000Z - 4 months ago

Vor Bio price target lowered to $40 from $55 at Stifel

Vor Bio doses first patient in UPSTREAM SjD study

2026-03-30T12:25:44.000Z - 4 months ago

Vor Bio doses first patient in UPSTREAM SjD study

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 8:01 AM EDT - 4 months ago

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

Vor Biopharma Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 4 months ago

Vor Biopharma Earnings release: Q4 2025

Vor Biopharma Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 4 months ago

Vor Biopharma Annual report: Q4 2025

Vor Bio initiated with a Buy at Jefferies

2026-03-29T23:30:08.000Z - 4 months ago

Vor Bio initiated with a Buy at Jefferies

Vor Bio to sell 5.338M shares at $14.05 in private placement

2026-03-27T12:27:35.000Z - 4 months ago

Vor Bio to sell 5.338M shares at $14.05 in private placement

Vor Bio Announces $75 Million Private Placement with TCGX

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Vor Bio Announces $75 Million Private Placement with TCGX

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 23, 2026, 4:30 PM EDT - 4 months ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio initiated with an Overweight at Wells Fargo

2026-03-19T10:01:01.000Z - 4 months ago

Vor Bio initiated with an Overweight at Wells Fargo

Vor Biopharma Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 5 months ago

Vor Biopharma Slides: Corporate presentation

Vor Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:50 AM EST - 5 months ago

Vor Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Feb 23, 2026, 8:00 AM EST - 5 months ago

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Vor Biopharma Registration statement: Registration Filing

Jan 29, 2026, 7:00 AM EST - 6 months ago

Vor Biopharma Registration statement: Registration Filing

Vor Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 7 months ago

Vor Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Vor Biopharma Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 7 months ago

Vor Biopharma Slides: 44th Annual J.P. Morgan Healthcare Conference

Vor Bio initiated with a Buy at Citi

2026-01-09T11:15:37.000Z - 7 months ago

Vor Bio initiated with a Buy at Citi

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 7 months ago

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Dec 23, 2025, 4:01 PM EST - 7 months ago

Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Vor Bio price target lowered to $46 from $64 at Baird

2025-12-23T12:00:24.000Z - 8 months ago

Vor Bio price target lowered to $46 from $64 at Baird

Vor Bio price target lowered to $40 from $43 at JPMorgan

2025-12-19T12:00:56.000Z - 8 months ago

Vor Bio price target lowered to $40 from $43 at JPMorgan

Vor Bio initiated with a Buy at TD Cowen

2025-12-17T10:40:21.000Z - 8 months ago

Vor Bio initiated with a Buy at TD Cowen

Vor Bio prices 13.88M shares at $10.81 in private placement

2025-12-15T13:05:06.000Z - 8 months ago

Vor Bio prices 13.88M shares at $10.81 in private placement

Vor Bio Announces $150 Million Private Placement

Dec 15, 2025, 8:00 AM EST - 8 months ago

Vor Bio Announces $150 Million Private Placement

Vor Bio initiated with an Overweight at JPMorgan

2025-12-09T10:00:19.000Z - 8 months ago

Vor Bio initiated with an Overweight at JPMorgan

Vor Biopharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 3:00 PM EST - 8 months ago

Vor Biopharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Vor Bio assumed with a Neutral at Wedbush

2025-11-25T13:41:07.000Z - 9 months ago

Vor Bio assumed with a Neutral at Wedbush

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 9 months ago

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Vor Biopharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Vor Biopharma Earnings release: Q3 2025

Vor Biopharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Vor Biopharma Quarterly report: Q3 2025

Vor Biopharma Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 2:30 PM EST - 9 months ago

Vor Biopharma Transcript: TD Cowen Immunology and Inflammation Summit

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Nov 10, 2025, 9:56 PM EST - 9 months ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Nov 10, 2025, 4:01 PM EST - 9 months ago

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Vor Biopharma Registration statement: Registration Filing

Nov 10, 2025, 7:00 AM EST - 9 months ago

Vor Biopharma Registration statement: Registration Filing

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Nov 8, 2025, 11:45 AM EST - 9 months ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Vor Bio to Participate in Upcoming Investor Conferences

Nov 7, 2025, 8:00 AM EST - 9 months ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Biopharma Slides: Corporate Presentation

Nov 3, 2025, 6:00 PM EST - 9 months ago

Vor Biopharma Slides: Corporate Presentation

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Nov 3, 2025, 8:00 AM EST - 9 months ago

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Oct 29, 2025, 11:01 AM EDT - 9 months ago

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Vor Biopharma Transcript: Study Update

Oct 28, 2025, 4:30 PM EDT - 9 months ago

Vor Biopharma Transcript: Study Update

Vor Biopharma Press release: Study Update

Oct 28, 2025, 4:30 PM EDT - 9 months ago

Vor Biopharma Press release: Study Update

Vor Biopharma Slides: Study Update

Oct 28, 2025, 4:30 PM EDT - 9 months ago

Vor Biopharma Slides: Study Update

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Oct 22, 2025, 4:30 PM EDT - 10 months ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Oct 17, 2025, 8:00 AM EDT - 10 months ago

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Oct 14, 2025, 8:00 AM EDT - 10 months ago

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Sep 29, 2025, 7:00 AM EDT - 11 months ago

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Vor Biopharma Registration statement: Registration Filing

Sep 24, 2025, 8:00 AM EDT - 11 months ago

Vor Biopharma Registration statement: Registration Filing

Vor Bio Appoints Navid Z. Khan, Ph.D.

Sep 23, 2025, 8:00 AM EDT - 11 months ago

Vor Bio Appoints Navid Z. Khan, Ph.D.

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Sep 17, 2025, 9:00 PM EDT - 11 months ago

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Sep 17, 2025, 4:15 PM EDT - 11 months ago

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Vor Biopharma Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 15, 2025, 4:00 PM EDT - 11 months ago

Vor Biopharma Transcript: Stifel Virtual Immunology and Inflammation Forum

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 12, 2025, 4:15 PM EDT - 11 months ago

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Vor Biopharma Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 11:15 AM EDT - 1 year ago

Vor Biopharma Transcript: Citi's Biopharma Back to School Conference

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Aug 27, 2025, 8:00 AM EDT - 1 year ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 13, 2025, 8:30 AM EDT - 1 year ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Vor Biopharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Vor Biopharma Quarterly report: Q2 2025

Vor Biopharma Proxy statement: Proxy Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Vor Biopharma Proxy statement: Proxy Filing

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 21, 2025, 8:30 AM EDT - 1 year ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 17, 2025, 8:30 AM EDT - 1 year ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 10, 2025, 4:00 PM EDT - 1 year ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:00 PM EDT - 1 year ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 1 year ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Jun 25, 2025, 4:45 PM EDT - 1 year ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Biopharma Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Vor Biopharma Quarterly report: Q1 2025

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025, 8:30 AM EDT - 1 year ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Biopharma Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Vor Biopharma Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Vor Biopharma Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Vor Biopharma Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Biopharma Registration statement: Registration Filing

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Registration statement: Registration Filing

Vor Biopharma Earnings release: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Vor Biopharma Earnings release: Q4 2024

Vor Biopharma Annual report: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Vor Biopharma Annual report: Q4 2024

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 13, 2025, 8:00 AM EST - 1 year ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Biopharma Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 12:00 PM EST - 1 year ago

Vor Biopharma Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Biopharma Registration statement: Registration Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

Vor Biopharma Registration statement: Registration Filing

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Jan 8, 2025, 9:00 AM EST - 1 year ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 1 year ago

Vor Bio Announces $55.6 Million Private Placement

Vor Biopharma Transcript: Status Update

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Transcript: Status Update

Vor Biopharma Press release: Status Update

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Press release: Status Update

Vor Biopharma Slides: Status Update

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Slides: Status Update

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Dec 9, 2024, 7:30 AM EST - 1 year ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Biopharma Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 2:25 PM EST - 1 year ago

Vor Biopharma Transcript: Stifel 2024 Healthcare Conference

Vor Biopharma Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Vor Biopharma Earnings release: Q3 2024

Vor Biopharma Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Vor Biopharma Quarterly report: Q3 2024

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 30, 2024, 7:00 AM EDT - 2 years ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

pc247cz
pc247cz Aug. 4 at 2:20 PM
$HUMA strongly believe in this swing idea. Also holding $VOR a monster in making 😅
0 · Reply
Lizardbronsen
Lizardbronsen Aug. 3 at 2:45 PM
$SPY $FCUV $AMZN $VOR $SCYX
0 · Reply
atmostrunmoney
atmostrunmoney Aug. 3 at 2:27 PM
$VOR VOR & $OMER bullish….
0 · Reply
GSP
GSP Aug. 3 at 12:42 PM
$SPY $FCUV $AMZN $VOR $SCYX
0 · Reply
GSP
GSP Aug. 2 at 3:13 PM
Your Day Trading Watch List Video for August 3rd in About 3 Minutes: $SPY $FCUV $AMZN $VOR $SCYX .
0 · Reply
MikiTrader
MikiTrader Aug. 1 at 4:39 AM
$VOR
0 · Reply
pc247cz
pc247cz Jul. 31 at 8:01 PM
$VOR nice recovery
0 · Reply
GSP
GSP Jul. 31 at 11:39 AM
$AVEX $GCTK $VOR $CYCU $JLHL
0 · Reply
GSP
GSP Jul. 30 at 10:17 PM
Your Day Trading Watch List for July 31st in About 2 Minutes (con't): $AVEX $GCTK $VOR $CYCU $JLHL .
0 · Reply
pc247cz
pc247cz Jul. 30 at 7:55 PM
$VOR Jist wow. Still not selling. More to come. 🙏
0 · Reply
galaxy_celebrity
galaxy_celebrity Jul. 29 at 1:58 PM
$VOR 50 $ on the way !! just be patient 💫💫
0 · Reply
StockConsultant
StockConsultant Jul. 29 at 1:28 PM
$VOR Vor Biopharma stock, watch for a bull flag breakout at https://stockconsultant.com/?VOR Breakout trade WATCH for possible breakout above 21.23 Target: 27.15, 35.7% Stop: 18.43 Loss: 7.9% P/L ratio: 4.5 : 1 - Excellent BULLISH [Timing] Strong bullish 3 day candlestick pattern with Mild 3 day accumulation. [Timing] Average bullish 1 day moneyflow [Timing] breakout watch above 21.23, no resistance in area just above. BEARISH [Positioning] Intermediate trend possibly bearish, Sideways trend near upper resistance. [Positioning] at resistance
1 · Reply
tradehulk
tradehulk Jul. 22 at 2:17 PM
$VOR 💥 🚨$CHAI about to trade 50M shares premarket! 💥
0 · Reply
RunnerSignals
RunnerSignals Jul. 21 at 8:08 PM
$VOR $HRMY $TROX $TXG $PLTK flipped red to green and finished strong. real accumulation or one-day squeeze? the closing tape leaves a clue
0 · Reply
StockConsultant
StockConsultant Jul. 20 at 1:19 PM
$VOR Vor Biopharma stock watch, pullback to 17.89 triple+ support area with high trade quality at https://stockconsultant.com/?VOR Long Trade Target 1: 24.54 Profit: 35.7% Stop/Trailing Stop: 16.54 Loss: 8.6% P/L ratio: 4.2 : 1 - Excellent Target 2: 26.67 Profit: 47.4% P/L ratio: 5.5 : 1 - Excellent Extreme rally BULLISH [Positioning] at support [Timing] Good bullish 1 day moneyflow BEARISH [Positioning] Intermediate trend possibly bearish, Sideways trend near upper resistance.
1 · Reply
Sarah147
Sarah147 Jul. 19 at 11:37 PM
$VOR has shifted its focus toward telitacicept, an autoimmune disease therapy licensed from RemeGen. The drug already has regulatory approval in China for at least one indication, reducing some development risk compared with an entirely novel preclinical program...
0 · Reply
Sarah147
Sarah147 Jul. 19 at 11:32 PM
$VOR need this to run
0 · Reply
pc247cz
pc247cz Jul. 17 at 4:18 PM
$GPCR and $VOR trade in same patterns. Interesting to watch.
0 · Reply
atmostrunmoney
atmostrunmoney Jul. 12 at 1:30 PM
$NEGG $NEGG, $SPCX , $OMER , $VOR all bullish.
0 · Reply
topstockalerts
topstockalerts Jul. 3 at 9:44 PM
$VOR feels stronger than it has any right to be
0 · Reply
focafoca99
focafoca99 Jul. 2 at 9:57 PM
$VOR offering inducement stock options and RSUs to seven new hires under Nasdaq Listing Rule 5635(c)(4).
0 · Reply
pc247cz
pc247cz Jul. 2 at 6:10 PM
$VOR Not selling yet.
0 · Reply